Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
30 studies found for:    "atypical hemolytic-uremic syndrome" OR "Hemolytic-Uremic Syndrome"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
2 Completed
Has Results
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
3 Completed
Has Results
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
4 Unknown  Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
Condition: Atypical Hemolytic Uraemic Syndrome.
Intervention:
5 Recruiting Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention:
6 Completed A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention:
7 Recruiting Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
8 Active, not recruiting aHUS Observational Long Term Follow-Up
Condition: Atypical Hemolytic Uremic Syndrome
Intervention:
9 Recruiting Complement Inhibition in aHUS Dialysis Patients
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: CCX168
10 Completed
Has Results
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: Eculizumab
11 Completed
Has Results
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: Eculizumab
12 Completed
Has Results
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
13 Unknown  The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention: Drug: Eculizumab
14 Not yet recruiting Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention: Biological: ALXN1210
15 Completed To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
Condition: ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
Intervention:
16 Enrolling by invitation Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Other: Clinical assessments and laboratory tests.
17 Completed Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
Conditions: Hemolytic-uremic Syndrome;   Escherichia Coli Infections
Intervention: Other: HUS standard coverage care (including in ICU)
18 Completed Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
Condition: Hemolytic Uremic Syndrome
Intervention: Drug: SYNSORB Pk
19 Recruiting Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adults
Condition: Hemolytic Uremic Syndrome
Intervention: Biological: Extra blood draw samples
20 Enrolling by invitation The Role of Microparticles as a Biomarker
Conditions: Atypical Hemolytic Uremic Syndrome;   Thrombotic Thrombocytopenic Purpura;   Microparticles;   Microangiopathic Hemolytic Anemia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.